Introduction – Clinical Research Department

  • Vijaya Medical & Educational Trust (VMET) was started in the year 1972 by Shri B. Nagi Reddy, a Philanthropist with the vision of selfless service to the community.
  • Since our inception in 1972, we (Vijaya Hospitals) have served millions of patients from India & abroad and have evolved into one of the premier multispecialty institutions in India.
  • Our hospital is NABH accredited and the laboratory service is NABL accredited.
  • Vijaya medical & Educational trust Clinical research department was formed in the year of 2009 and is committed to delivering secure, responsive, high-quality, customer-oriented services and support that foster excellence in clinical care and biomedical research.
  • We support and are glad to be a part of a secure, dependable technical environment that supports the increasing requirements that evolve with improving clinical systems of drug development for the growth of the healthcare industry.
  • We wish to join hands with pharmaceutical industries and biotechnology companies across the globe for product development in conducting clinical trials from phase I to phase IV and Bio-medical research studies to ensure better patient care.
  • We have constituted VCMR (Vijaya Clinical and Medical Research) for interventional clinical studies and the VBMHR Ethics committee for non-interventional and academic studies in our VMET for
  • We have highly qualified and learned persons in our research team.
SI No. Title PI Phase Year
1 Aldosterone blockade for Health Improvement Evaluation in End- Stage renal diseases Dr. Radha Venkatramanan III 2019
2 An open label, multicenter Post Marketing Surveillance Study in India to assess safety and efficacy of Intramuscular administration of stempeucel® in patients with critical limb ischemia due to Buerger’s disease Dr. M. Rajkumar IV 2018

A Phase 3, Open label, multicenter, triple arm, Randomized clinical trial to determine the efficacy of dehydrated human amnion chorion membrane allograft (AmchoPlast®) and dehydrated human amnion chorion membrane allograft – Polyhexamethylene Biguanide (AmchoPlast PHMB®) with Standard Care Compared with Standard Care alone in treatment of acute wounds.

Dr. M. Rajkumar III 2021
4 Ivabradine OD: Post marketing observational study (PMOS) A Post marketing observational study to determine the average resting heart rate in patients receiving Ivabradine once daily formulation. Dr. Vijaya Kumar IV 2021

An open label, multicentre, randomized phase IV clinical trial to evaluate the safety and efficacy of MaxioCel compared with Aquacel Extra for the management of exuding chronic wounds

Dr. M. Rajkumar III 2022
Sl No. Title PI Phase Year
1 A Phase IIb prospective, randomized, double-blind, placebo controlled, multiceter dose escalation study of NTx R-265 : human chorionic gonadotropin (HCG) and epotin Alfa (EPO) in acute ischemic stroke patients (REGENESIS-LED) Dr. Suresh Kumar IIB 2009
2 Long time safety of open label pramipexole extended release (ER) in patient with early Parkinson diseases Dr. Suresh Kumar III 2008
3 A Double blind, double dummy, placebo –controlled, randomized three parallel groups study comparing the efficacy, safety and tolerability of pramipexole ER versus, placebo and versus pramipexole IR administrated orally over a 26 weeks maintenance phase in patients with early Parkinson’s diseases(PD) Dr. Suresh Kumar III 2008
4 Protocol Number: 28850: open- label, trial to determine the long term safety of safinamide in parkinson’s Diseases patient. Dr. Suresh Kumar III 2009
5 Prospective randomized12 week controlled study of visual field change in subs with partial seizures receiving pregablin or placebo Dr. Suresh Kumar III 2010
6 Multicenter, Double –Blind, Placebo-controlled, Dose –ranging study to determine the safety and efficacy of Daclizumab HYP (DAC HYP) as a Monotherapy treatment in subject with relapsing- Remitting Multiple Sclerosis Dr. Suresh Kumar III 2010
7 A Multicenter, , Randomized, double blind, placebo-controlled, 5 arm ,Parallel-group study to assess Rotigotine transdermal system dose response in subject with advanced-stage parkinson’s diseases. Dr. Suresh Kumar III 2010
8 Efficasy and Safety of esclicarbazapire actate (BIA 2-093) as adjuctive therapy for refractory partial seizures in a double blind –Randomized , placebo-controlled, multicenter trial.  Dr. Suresh Kumar III 2011
9 SAVE- An international, Multicenter. Open , parallel group, prospective, randomized, controlled trial to determine the effectiveness of treatment with continuous +V airways pressure (CPAP) in addition to standard care in reducing CV Morbidity and nortality in patients with Co existing CV Diseases and moderate- severe abstructive sleep apnea(OSA) Dr. Suresh Kumar III 2011
10 A Randomized, Double -blinded, placebo- controlled, six- month study to Evaluate the efficacy, safety and tolerability of SARIZOTAN in patients with RETT syndrome with respiratory symptoms Dr. Suresh Kumar III
11 A Label Extension, Single Arm Multicentric Phase Iii Study To Assess The Efficacy And Safety Of Stempeucel® (Adult Human Bone Marrow Derived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells) In Patients With Critical Limb Ischemia Due To Atherosclerotic Peripheral Arterial Disease Dr. M. Rajkumar III 2018
12 Open-Label, Long-Term, Extension Treatment using Intra-Erythrocyte Dexamethasone sodium phosphate in patients with Ataxia Telangiectasia who participated in the IEDAT-02-2015 Study Dr. Suresh Kumar III 2021
13 Anti-coronavirus therapies (ACT) to prevent progression of  mild COVID-19: Randomized trials Dr. Thilagavathi III 2018

Book an Appointment Now!

Please feel welcome to contact our friendly reception staff with any general or medical enquiry. Our doctors will receive or return any urgent calls.

  • Experienced Specialist Doctors
  • Excellent Nursing Care
  • Excellent Patient Care
  • Friendly Ambience
  • Equal treatment